OBJECTIVE: Antibodies toward the citrullinated form of the synovial antigen vimentin are specific for rheumatoid arthritis (RA) and are associated with HLA-DRB1*0401. This suggests that T cells specific for peptides derived from citrullinated vimentin presented in the context of HLA-DRB1*0401 may contribute to the etiopathogenesis of RA. The aim of this study was to identify immunodominant epitopes from citrullinated vimentin presented by HLA-DRB1*0401 and to characterize the resulting T cell responses. METHODS: We first predicted an HLA-binding T cell epitope from citrullinated vimentin based on the binding motif of HLA-DRB1*0401 and then confirmed its affinity. A class II major histocompatibility complex (MHC) tetramer loaded with the citrullinated form of vimentin aa 59-78 (cit-vimentin aa 59-78) was constructed and used to screen for specific T cells in HLA-DRB1*0401-transgenic mice, patients with RA, and healthy control subjects. Additionally, the cytokine output following cit-vimentin aa 59-78 challenge was analyzed in patients and healthy control subjects by multicolor flow cytometry and Luminex-based analysis. RESULTS: The citrullinated form of vimentin aa 59-78 bound to HLA-DRB1*0401, but the native form could not. Subsequently, cit-vimentin aa 59-78-specific T cells were detected in immunized mice and in the periphery of both HLA-DR*0401-positive healthy control subjects and HLA-DR*0401-positive patients with RA, using class II MHC tetramers, CD154 up-regulation, and intracellular cytokine measurements. As demonstrated in cell culture supernatants, the production of cytokines (predominantly interferon-γ) in response to cit-vimentin aa 59-78 was significantly higher in patients compared with controls. CONCLUSION: Here, we describe a posttranslational modification of an RA candidate autoantigen toward which HLA-DRB1*0401-restricted T cells can be detected in both patients with RA and healthy controls but for which a proinflammatory response is observed uniquely in patients with RA.
OBJECTIVE: Antibodies toward the citrullinated form of the synovial antigen vimentin are specific for rheumatoid arthritis (RA) and are associated with HLA-DRB1*0401. This suggests that T cells specific for peptides derived from citrullinated vimentin presented in the context of HLA-DRB1*0401 may contribute to the etiopathogenesis of RA. The aim of this study was to identify immunodominant epitopes from citrullinated vimentin presented by HLA-DRB1*0401 and to characterize the resulting T cell responses. METHODS: We first predicted an HLA-binding T cell epitope from citrullinated vimentin based on the binding motif of HLA-DRB1*0401 and then confirmed its affinity. A class II major histocompatibility complex (MHC) tetramer loaded with the citrullinated form of vimentin aa 59-78 (cit-vimentin aa 59-78) was constructed and used to screen for specific T cells in HLA-DRB1*0401-transgenic mice, patients with RA, and healthy control subjects. Additionally, the cytokine output following cit-vimentin aa 59-78 challenge was analyzed in patients and healthy control subjects by multicolor flow cytometry and Luminex-based analysis. RESULTS: The citrullinated form of vimentin aa 59-78 bound to HLA-DRB1*0401, but the native form could not. Subsequently, cit-vimentin aa 59-78-specific T cells were detected in immunized mice and in the periphery of both HLA-DR*0401-positive healthy control subjects and HLA-DR*0401-positive patients with RA, using class II MHC tetramers, CD154 up-regulation, and intracellular cytokine measurements. As demonstrated in cell culture supernatants, the production of cytokines (predominantly interferon-γ) in response to cit-vimentin aa 59-78 was significantly higher in patients compared with controls. CONCLUSION: Here, we describe a posttranslational modification of an RA candidate autoantigen toward which HLA-DRB1*0401-restricted T cells can be detected in both patients with RA and healthy controls but for which a proinflammatory response is observed uniquely in patients with RA.
Authors: K N Verpoort; C M Jol-van der Zijde; E A M Papendrecht-van der Voort; A Ioan-Facsinay; J W Drijfhout; M J D van Tol; F C Breedveld; T W J Huizinga; R E M Toes Journal: Arthritis Rheum Date: 2006-12
Authors: O Snir; M Widhe; C von Spee; J Lindberg; L Padyukov; K Lundberg; A Engström; P J Venables; J Lundeberg; R Holmdahl; L Klareskog; V Malmström Journal: Ann Rheum Dis Date: 2008-07-17 Impact factor: 19.103
Authors: K N Verpoort; K Cheung; A Ioan-Facsinay; A H M van der Helm-van Mil; J K de Vries-Bouwstra; C F Allaart; J W Drijfhout; R R P de Vries; F C Breedveld; T W J Huizinga; G J M Pruijn; R E M Toes Journal: Arthritis Rheum Date: 2007-12
Authors: Jonathan A Hill; David A Bell; William Brintnell; David Yue; Bret Wehrli; Anthony M Jevnikar; David M Lee; Wolfgang Hueber; William H Robinson; Ewa Cairns Journal: J Exp Med Date: 2008-04-07 Impact factor: 14.307
Authors: Cliff Rims; Hannes Uchtenhagen; Mariana J Kaplan; Carmelo Carmona-Rivera; Philip Carlucci; Katalin Mikecz; Adrienn Markovics; Jeffrey Carlin; Jane H Buckner; Eddie A James Journal: Arthritis Rheumatol Date: 2019-03-08 Impact factor: 10.995
Authors: Yi Tian Ting; Jan Petersen; Sri H Ramarathinam; Stephen W Scally; Khai L Loh; Ranjeny Thomas; Anish Suri; Daniel G Baker; Anthony W Purcell; Hugh H Reid; Jamie Rossjohn Journal: J Biol Chem Date: 2018-01-09 Impact factor: 5.157
Authors: Jennifer Pieper; Anatoly Dubnovitsky; Christina Gerstner; Eddie A James; Mary Rieck; Genadiy Kozhukh; Karolina Tandre; Sara Pellegrino; John A Gebe; Lars Rönnblom; Tatyana Sandalova; William W Kwok; Lars Klareskog; Jane H Buckner; Adnane Achour; Vivianne Malmström Journal: J Autoimmun Date: 2018-05-28 Impact factor: 7.094
Authors: Joerg Ermann; Deepak A Rao; Nikola C Teslovich; Michael B Brenner; Soumya Raychaudhuri Journal: Nat Rev Rheumatol Date: 2015-06-02 Impact factor: 20.543
Authors: Manon A A Jansen; Rachel Spiering; Femke Broere; Jacob M van Laar; John D Isaacs; Willem van Eden; Catharien M U Hilkens Journal: Immunology Date: 2017-09-18 Impact factor: 7.397